Andere indicaties:

Dystonie:

Fox S.H., Kellett M., Moore A.P., Crossman A.R., Brotchie J.M. (2002). Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders. Jan;17(1):145-9. 

Nabilone/ oraal

Consroe P., Sandyk R., Snider S.R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience;30(4):277-282.

 CBD/ oraal

Sandyk R., Snider S.R., Consroe P., Elias S.M. (1986). Cannabidiol in dystonic movement disorders. Psychiatry Research. Jul;18(3):291.

CBD/ oraal

Snider S.R., Consroe P. (1984). Treatment of Meige's syndrome with cannabidiol. Neurology;34(Suppl):147.

CBD/ oraal

Epilepsie:

Ames F.R., Cridland S. (1986). Anticonvulsant effect of cannabidiol. South African Medical Journal;69(1):14

CBD/ oraal

Cunha J.M., Carlini E.A., Pereira A.E., Ramos O.L., Pimentel C., Gagliardi R., Sanvito W.L., Lander N., Mechoulam R. (1980). Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology;21(3):175-185.

CBD/ oraal

Consroe P.F., Wood G.C., Buchsbaum H. (1975). Anticonvulsant nature of marihuana smoking. Journal of the American Medical Association;234(3):306-307.

Cannabis/ inhalatie

Ziekte van Alzheimer:

Volicer L., Stelly M., Morris J., McLaughlin J., Volicer B.J. (1997). Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry;12(9):913-919.

THC/ oraal

Anorexia Nervosa:

Gross H., Ebert M.H., Faden V.B., Goldberg S.C., Kaye W.H., Caine E.D., Hawks R., Zinberg N. (1983). A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. Journal of Clinical Psychopharmacology;3(3):165-171.

THC/ oraal

Ziekte van Huntington:

Consroe P., Laguna J., Allender J., Snider S., Stern L., Sandyk R., Kennedy K., Schram K. (1991). Controlled clincal trial of cannabidiol in Huntington's disease. Pharmacology, Biochemistry and Behavior; 40(3):701-8.

CBD/ oraal